All questionsPharmacology: Xtandi (enzalutamide), all indications4 questions · 2 sourcesMechanismHow does Xtandi work (mechanism of action)?“XTANDI is an androgen receptor inhibitor that acts on multiple steps of the androgen receptor signaling pathway within the tumor cell1” (opens the source at this quote in a new tab)CopyFlag“Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Xtandi metabolized?“Enzalutamide is primarily eliminated by hepatic metabolism.” (opens the source at this quote in a new tab)CopyFlag“Enzalutamide is metabolized by CYP2C8 and CYP3A4. CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide). Carboxylesterase 1 metabolizes N-desmethyl enzalutamide and enzalutamide to the inactive carboxylic acid metabolite.” (opens the source at this quote in a new tab)CopyFlagHow long does Xtandi stay in your system (half-life)?“The mean terminal half-life (t1/2) for enzalutamide after a single oral dose is 5.8 days (2.8 to 10.2 days). The mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.” (opens the source at this quote in a new tab)CopyFlag“Enzalutamide achieves steady-state by Day 28 and its AUC accumulates approximately 8.3-fold relative to a single dose.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Xtandi?“XTANDI is available as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide. XTANDI is also available as film-coated tablets for oral administration. Each tablet contains 40 mg or 80 mg of enzalutamide. The inactive ingredients are hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, and magnesium stearate. The tablet film-coat contains hypromellose, talc, polyethylene glycol, titanium dioxide, and ferric oxide.” (opens the source at this quote in a new tab)CopyFlag